Goodwin Advises VelaVigo on Exclusive Option Agreement With Avenzo to License Nectin4/TROP2 Bispecific Antibody-Drug Conjugate for Up To $750 Million
December 18, 2024
December 18, 2024
BOSTON, Massachusetts, Dec. 18 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised VelaVigo Cayman Limited ("VelaVigo") on an agreement with Avenzo Therapeutics, Inc. ("Avenzo") granting Avenzo an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China). VelaVigo will maintain rights for Greater China and plans . . .
The Life Sciences team advised VelaVigo Cayman Limited ("VelaVigo") on an agreement with Avenzo Therapeutics, Inc. ("Avenzo") granting Avenzo an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China). VelaVigo will maintain rights for Greater China and plans . . .